Nasdaq Copenhagen

ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy

Retrieved on: 
Monday, June 27, 2022

ALK initiates a Phase I clinical trial of its novel investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy.

Key Points: 
  • ALK initiates a Phase I clinical trial of its novel investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy.
  • The trial marks the formal start of clinical development of the peanut SLIT-tablet which uses same technology as ALKs SLIT-tablets for respiratory allergies.
  • ALK announced today that it is initiating Phase I clinical development of its investigational SLIT-tablet for the treatment of peanut allergy.
  • The Alliance trial is a Phase I, open-label, dose-escalation, multi-centre trial, with participants screened via double-blind, placebo-controlled food challenges to confirm their peanut allergy.

Camp Huronda welcomes back campers for a long-awaited reopening and unveils the new Insul-Inn

Retrieved on: 
Thursday, June 23, 2022

On June 26th, Camp Huronda staff and partners will unveil the newly built Insul-Inn, and welcome families back to the highly anticipated re-opening of the summer camp season.

Key Points: 
  • On June 26th, Camp Huronda staff and partners will unveil the newly built Insul-Inn, and welcome families back to the highly anticipated re-opening of the summer camp season.
  • "After two years of virtual camp, campers can finally get back to doing what they love at their home-away-from-home.
  • Not only do Camp Huronda's on-site medical professionals provide specialized healthcare to campers, many also live with type 1 diabetes.
  • "Camp Huronda helped me learn to manage my diabetes and gave me an incredible camp experience," says Taylor Hall, former Camp Huronda camper and current camp counsellor.

Moderated Webcast with BioPorto’s Management

Retrieved on: 
Tuesday, June 21, 2022

COPENHAGEN, Denmark and BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (CPH:BIOPOR) (BioPorto) today provided details of a previously announced session with members of its management team.

Key Points: 
  • COPENHAGEN, Denmark and BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (CPH:BIOPOR) (BioPorto) today provided details of a previously announced session with members of its management team.
  • Tony Pare, CEO, and Neil Goldman, Executive VP & CFO, will participate in a webcast hosted by HC Andersen Capital (HCA) on Wednesday, June 29, 2022, at 2:00 p.m. CET (8:00 a.m.
  • With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies.
  • The NGAL Test is CE marked and registered in a number of countries worldwide.

BioPorto Appoints World Leading Expert and Pioneer on the Clinical Utility of the NGAL Biomarker, Dr. Prasad Devarajan, MD FAAP FASN, as New Senior Medical Director

Retrieved on: 
Monday, June 20, 2022

Dr. Devarajan is considered a world leading Pediatric Nephrologist and physician-scientist and a pioneer in understanding the relationship between Neutrophil gelatinase-associated lipocalin (NGAL) and Acute Kidney Injury (AKI).

Key Points: 
  • Dr. Devarajan is considered a world leading Pediatric Nephrologist and physician-scientist and a pioneer in understanding the relationship between Neutrophil gelatinase-associated lipocalin (NGAL) and Acute Kidney Injury (AKI).
  • Dr. Devarajan will share his time between his directorships at Cincinnati Childrens and his executive role at BioPorto.
  • I am extremely excited and proud to have a world-renowned nephrologist and NGAL expert join BioPorto as Senior Medical Director, said Tony Pare, BioPortos Chief Executive Officer.
  • I have been working with BioPorto for many years and am truly impressed with The NGAL Test and its unique potential to save lives.

New Custom made by ReSound rechargeable hearing aids: the most advanced technology in a stylish design 

Retrieved on: 
Thursday, June 16, 2022

GN Hearing, the global leader in hearing aid innovation, today announces the most advanced, rechargeable Custom made by ReSound hearing aids .

Key Points: 
  • GN Hearing, the global leader in hearing aid innovation, today announces the most advanced, rechargeable Custom made by ReSound hearing aids .
  • Custom made by ReSound hearing aids offer medical-grade, customized, full-time hearing support and care, whereas the recently launched Jabra Enhance Plus is intended for people needing occasional hearing support.
  • View the full release here: https://www.businesswire.com/news/home/20220616005063/en/
    Runner wearing Custom made by ReSound hearing aids (Photo: Business Wire)
    According to research, 58% of people try headphones to help with their hearing, before moving onto hearing aids*.
  • Now they can get a stylish, custom made hearing aid with expertise and support from a hearing care professional.

Beltone Introduces Custom Rechargeable Hearing Aids in a Modern Earbud Design

Retrieved on: 
Thursday, June 16, 2022

GLENVIEW, Ill., June 16, 2022 /PRNewswire/ -- Beltone, winner of Newsweek's "Best in Hearing Care Retailers" award revealed today that it has once again expanded its product line with the introduction of the new Beltone Imagine™ Custom rechargeable hearing aids. The new hearing aids restore natural hearing in a sleek and comfortable earbud design. They are available in modern In-style™ or Blend-In colors, are weather-and-sweatproof, and last all day on a single battery charge.

Key Points: 
  • The innovative hearing aids are weatherproof, rechargeable, and custom made allowing for all day comfort, making them ideal for all lifestyles
    GLENVIEW, Ill., June 16, 2022 /PRNewswire/ -- Beltone , winner of Newsweek's "Best in Hearing Care Retailers" award revealed today that it has once again expanded its product line with the introduction of the new Beltone Imagine Custom rechargeable hearing aids .
  • The new hearing aids restore natural hearing in a sleek and comfortable earbud design.
  • "Because of their modern design, these new custom rechargeable hearing aids offer a different approachto treating hearing loss than what is traditionally thought of for hearing aids, and we are excited for those ready to start their hearing health journey with Beltone."
  • To add to the ultimate personalized experience, users will receive custom charger to pair with their custom hearing aids.

Zealand Pharma completes registration of capital increase

Retrieved on: 
Friday, June 3, 2022

3/2022, Zealand Pharma A/S ("Zealand") announces that it has today, as part of completion of a directed issue and private placement (the "Private Placement"), registered with the Danish Business Authority, the capital increase of DKK 2,892,368, divided into 2,892,368 ordinary shares (the "New Shares").

Key Points: 
  • 3/2022, Zealand Pharma A/S ("Zealand") announces that it has today, as part of completion of a directed issue and private placement (the "Private Placement"), registered with the Danish Business Authority, the capital increase of DKK 2,892,368, divided into 2,892,368 ordinary shares (the "New Shares").
  • The amendments to Zealand's articles of association required by the capital increase have been registered today with the Danish Business Authority.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines.
  • All such forward-looking statements speak only as of the date of this press release and are based on information available to Zealand Pharma as of the date of this release.

Zealand Pharma announces directed issue and private placement corresponding to approx. 6.6 % of existing share capital

Retrieved on: 
Wednesday, June 1, 2022

Zealand Pharma announces directed issue and private placement corresponding to approx.

Key Points: 
  • Zealand Pharma announces directed issue and private placement corresponding to approx.
  • 6.6% of Zealand's currently registered share capital, to certain reputable institutional shareholders (the "Private Placement").
  • The subscription price equals the price for Zealand's shares quoted on Nasdaq Copenhagen at the time the Private Placement was made.
  • Danske Bank A/S and Nordea Danmark, Filial af Nordea Bank Abp, Finland are acting as joint global coordinators for the Private Placement.

SheerlinkTM Expands Audio Module Series

Retrieved on: 
Wednesday, June 1, 2022

In association with the NAMM show in Anaheim, California (June 3-5, 2022), RTX A/S, (NASDAQ Copenhagen: RTX A/S), a leader in the design of resilient wireless audio solutions, today announced the expansion of their audio module series supporting the Sheerlink product solutions.

Key Points: 
  • In association with the NAMM show in Anaheim, California (June 3-5, 2022), RTX A/S, (NASDAQ Copenhagen: RTX A/S), a leader in the design of resilient wireless audio solutions, today announced the expansion of their audio module series supporting the Sheerlink product solutions.
  • The new RTX1291 2.4GHz module bears strong relations to the RTX1290 module but fits additional purposes due to its higher DSP performance.
  • View the full release here: https://www.businesswire.com/news/home/20220601005677/en/
    RTX1291 2.4GHz audio module (Photo: Business Wire)
    RTX Sheerlink solutions for wireless audio products significantly reduce the complex wireless audio engineering and, what really matters these days, the uncertainty of the supply chain.
  • Multiple wireless configurations are available in the Sheerlink solution family, each with its own product use cases in mind.

Restructuring proposal adopted by creditors

Retrieved on: 
Monday, May 30, 2022

Copenhagen, Denmark, May 30, 2022 Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (Orphazyme or the Company), a late-stage biopharmaceutical company, announces that today an in-court meeting was held where the restructuring proposal as published by the Company through company announcement no.

Key Points: 
  • Copenhagen, Denmark, May 30, 2022 Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (Orphazyme or the Company), a late-stage biopharmaceutical company, announces that today an in-court meeting was held where the restructuring proposal as published by the Company through company announcement no.
  • Following the adoption of the restructuring proposal, the restructuring proceedings will be discontinued with immediate effect in accordance with the approved and affirmed restructuring proposal.
  • In continuance hereof, Orphazyme will transfer of substantially all of its assets and business activities to KemPharm Denmark A/S (please see company announcement no.
  • Subsequently Orphazyme will pay the undisputed debts to its creditors in accordance with the restructuring proposal.